Innovation and Commercialization
CAST has established several agreements with industry partners related to drug discovery for substance use and mental health disorders. We continue our excellence in drug discovery through structural and small molecule based medicinal chemistry.
Aether Therapeutics
Aether Therapeutics is an emerging biopharmaceutical company focused on curing diseases associated with the opioid epidemic and finding better therapies for pain.
The Aether team combines decades of successful drug development experience focused on curing diseases not simply treating symptoms.
Filament Health
Filament Health is a clinical-stage natural psychedelic drug development company. Filament’s mission is to see that safe, natural psychedelics are available to
everyone who needs them, as soon as possible.
LifeInSight BioTherapeutics
LifeInSight BioTherapeutics was established to fund collaborative research designed to optimize treatments for mental illness and SUDs. In 2016, a team of elite scientists from some of the most prestigious medical universities in the country formed an
alliance to develop such treatments. CAST collaborated with LifeInSight to produce educational videos (links below) on topics SUDs and other brain disorders.
LIS Addiction 55 - Addiction and Substance Use Disorders
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is committed to developing a better understanding of brain circuitry and targeting the specific circuits that misfire in brain disorders. By
combining proprietary technologies to identify and treat the defining symptoms of some of the most challenging central nervous system disorders, MapLight is introducing novel therapeutics that will bring hope and relief to countless patients.
Spark Biomedical, Inc.
Spark Biomedical, Inc.’s mission is to eliminate opioid addiction worldwide by working to address the full opioid addiction lifecycle. Spark developed the
Sparrow Ascent, the only FDA-cleared, drug-free, non-addictive, non-invasive, wearable treatment technology for the relief of opioid withdrawal symptoms.
Gulf Coast Consortia
The Gulf Coast Consortia (GCC) brings together the strengths of its six member institutions to build interdisciplinary collaborative research teams and training programs in the biological sciences at their intersection with the computational, chemical,
mathematical, and physical sciences. Comprised of six prominent and geographically proximate Gulf Coast institutions, Baylor College of Medicine, Rice University, University of Houston, University of Texas Health Science Center at Houston, University
of Texas Medical Branch at Galveston and University of Texas M. D. Anderson Cancer Center, the GCC's goal is to provide a cutting edge collaborative training environment and research infrastructure, one beyond the capability of any single institution. The
GCC's mission is to train the next generation of bioscientists and to enable scientists to ask and answer questions that cross scientific disciplines to address the challenging biological issues of our time and, ultimately, to apply the resulting
expertise and knowledge to the treatment and prevention of disease.